617-P: Current Practices and Gaps in Management of Type 2 Diabetes Mellitus (T2DM) with Dyslipidemia as per American Diabetes Association (ADA) Guidelines Subset Analysis from LEADD (Learning with Experts to Advance Diabetic Dyslipidemia Management) Study

Abstract

Background: CAD (Coronary Artery Disease) and diabetes is strongly associated with high low-density lipoproteins (LDL) levels. Objective: Understand evaluation practices and treatment for dyslipidemia with statin intensity in T2DM participants as per ADA guidelines. Methods: A subset analysis of real world, prospective, cross sectional, observational LEADD study in T2DM participants conducted at 226 sites. “n”=number of participants analyzed for each parameter. Available lipid profile was recorded and stratified based on age and Atherosclerotic cardiovascular disease (ASCVD) risk factors and ASCVD as per ADA guidelines for percentages achieving LDL-C target and high intensity of statin. Results: A total of 4002 participants enrolled with mean (±SD) Hb1Ac 8.15 ± 1.7%, LDL- C levels 117.7 ± 37.6 mg/dl. Rosuvastatin was given in 87% (n=2419/2757) participants. Participants <40 years, ASCVD risk factors and ASCVD were present in 95% (n=207/217) and 3.2% (n=7/217), in >40 years it was 86.7% (n=2908/3354) and 12.8% (n= 432/3354). Mean (±SD) LDL- C levels in ASCVD risk factors and ASCVD participants in <40 years was 129±37.9 mg/dl and 121±42mg/dl, in >40 years it was 120.9±36mg/dl and 118±41mg/dl. 64% (n= 155/162) and 80% (n= 4/5) participants <40 years with ASCVD risk factors and ASCVD, in >40 years 91.4% (n= 1925/2104) and 87.9% (278/316) were not on target LDL - C levels. In <40 years 15.6% (n = 22/141) and 83% (n = 5/6) statin receiving participants in the ASCVD risk factors and ASCVD group and in >40 years 87% (n = 1869/2143) and 77.8% (n = 271/348) were not receiving high intensity statins. Conclusion: Adherence to ADA guidelines for diabetic participants despite having ASCVD risk factors/ASCVD was sub-optimal in study participants, when high intensity statins is required for dyslipidemia to achieve desired outcomes in them. The findings need further research. Disclosure A. Unnikrishnan: Other Relationship; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddys Laboratories, Eli Lilly and Company, Eris Pharmaceuticals, Ipca Laboratories Ltd., MSD, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Sanofi. A.K. Das: None. B.D. Saboo: None. S. Kalra: None. V. Ayyar: None. M.H. Tiwaskar: None. Funding Diabetes Care India; Dr. Reddy's Laboratories